FORM 4

Check this box if no longer subje

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

ct	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GORMAN KEVIN CHARLES					2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX											ionship of Reporting F all applicable) Director		g Pe	10% Ov	vner
(Last) (First) (Middle) 12780 EL CAMINO REAL					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2024										Officer (give title below) Chief Execution		utive	Other (s below) e Officer	specify	
(Street) SAN DIEGO CA 92130			4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)										ridual or Joint/Group Filing (Check Application Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(St	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instr										ıct, instr		ten pl	an that is inte	ended to	
		Table	I-	Non-Deriva	tive S	Secui	rities	Acc	quir	ed, Di	sposed	of, o	r Be	nefici	ally	Own	ed			
Date			2. Transaction Date (Month/Day/Ye	Execution		n Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									ode	V	Amount	(A) or (D)	Pric	ce		Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 01			01/31/2024	24			S			2,707	D	D \$140.0		502,188 ⁽³⁾		2,188(3)		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if a	. Deemed ecution Date, iny onth/Day/Year)	4. Transaction Code (Instr. 8) 5. Nun of Deriva Securi Acquii (A) or Dispos of (D) (Instr. and 5)			ative rities ired osed	Exp	piration l	exercisable and on Date Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Deriv Secu	Price of ivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	, G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	V (A) (D)		Date Exercisa		Expiration ble Date		o	lumber of Shares						

Explanation of Responses:

- 1. Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$139.74 to \$142.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Remarks:

/s/ Darin Lippoldt, Attorneyin-Fact

02/02/2024

Date ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.